Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.45 |
| ▸ | PER2 | O15055 | 8/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CRY1 | Q16526 | 4/20 | 0.42 |
| ▸ | CRY2 | Q49AN0 | 4/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL608284 | 0.93 | RAD52 (0.44) | RAD52DNM1BACE1PER2POLB | |
| SCHEMBL607629 | 0.73 | BAX (0.59) | RAD52DNM1PER2MEN1KMT2A | |
| SCHEMBL608303 | 0.71 | RAD52 (0.53) | RAD52BACE1PER2POLBLMNA | |
| SCHEMBL607018 | 0.70 | RAD52 (0.97) | RAD52BACE1PER2POLBLMNA | |
| Hydrochloric Acid SCHEMBL22609687 | 0.69 | RAD52 (1.00) | RAD52BACE1PER2POLBLMNA | |
| SCHEMBL609435 | 0.68 | LMNA (0.75) | RAD52DNM1BACE1POLBLMNA | |
| SCHEMBL8775410 | 0.68 | SLC6A2 (0.49) | — | |
| SCHEMBL11775230 | 0.68 | DPP4 (0.36) | RAD52MEN1KMT2A | |
| SCHEMBL14889275 | 0.67 | BACE1 (1.00) | RAD52DNM1BACE1PER2POLB | |
| SCHEMBL11708027 | 0.66 | SIGMAR1 (0.50) | POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237887-B1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | SERONO LAB (CH) | 2008-06-04 | — | — | EP | claimed |
| EP-1094063-A1 | 9-(Piperazinylalkyl)carbazoles as Bax-modulators | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-25 | — | — | EP | claimed |
| US-8410110-B2 | 9-(piperazinylalkyl) carbazoles as Bax-modulators | MERCK SERONO SA (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120040933-A1 | 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2012-02-16 | — | — | US | disclosed |
| US-8053436-B1 | 9-(piperazinylalkyl) carbazoles as bax-modulators | MERCK SERONO SA (CH) | 2011-11-08 | — | — | US | disclosed |
| EP-1237887-B1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | SERONO LAB (CH) | 2008-06-04 | — | — | EP | disclosed |
| EP-1237887-A1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001029028-A1 | 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-04-26 | — | — | WO | disclosed |
| EP-1094063-A1 | 9-(Piperazinylalkyl)carbazoles as Bax-modulators | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040933-A1 | 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | BCL2, BAX, BAD | RAD52 3656/4885DNM1 2096/4885BACE1 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.